ANNUAL REVIEW: 2021/2022

Mission
To enable patients and professionals to work in partnership to drive policy and the regulatory environment in support of lung health at the European level, and to participate in and communicate about projects related to respiratory health and disease.

Vision
To improve lung health and advance diagnosis, treatment and care to ensure that every breath counts.

Overall objectives
1. Promote and protect the physical and mental health of sufferers of lung diseases and their related risks;
2. Advance the education and understanding of the public about lung diseases and their related risk factors;
3. Promote research into the field of lung diseases for the public benefit; and
4. Contribute to the fulfilment of the objectives of the ELF and ERS, which include the conduct of similar initiatives and actions in the area of the research, education and treatment of lung diseases.
ANNUAL FOCUS: Capacity building

ACHIEVEMENTS:

• Dec 2021 – first employee employed with a focus on development and engagement
• Jan 2022 – second employee employed with a focus on policy and dissemination
• Rename of European Lung Foundation Europe to Lungs Europe
• Creation of website

• Successful in becoming third party in EU projects:
  o UNITE4TB
  o OPTIMA
• Successful in becoming patient partner in COCOS-PFF project
• Kick off of UNITE4TB

UNITE4TB is the newest project of the IMI AMR Accelerator, an Innovative Medicines Initiative (IMI)-funded EU project with the shared goal of progressing the development of new medicines to treat or prevent resistant bacterial infections. The 7-year, project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active TB treatment regimens for drug-resistant and -sensitive TB. Learn more on the UNITE4TB website.

• Kick off of OPTIMA

OPTIMA is an Innovative Medicines Initiative (IMI)-funded EU project aiming to ensure that every patient with lung, prostate and breast cancer has access to the most up-to-date individualized treatments and innovative therapies. It is doing this by strengthening shared decision-making using dynamic computer-interpretable guidelines, and using AI-driven technology and tools. Learn more on the OPTIMA website.